Google DeepMind is a British-American artificial intelligence research laboratory and subsidiary of Google. It was founded in 2010 and acquired by Google in 2014. DeepMind is focused on building the next generation of AI systems safely and responsibly, with the mission to benefit humanity. They have achieved significant breakthroughs in AI, including creating neural network models that learn to play video games like humans, developing AlphaGo which defeated a Go world champion, and advancing protein folding with AlphaFold.

Google DeepMind

AI in Pharma: Discovery is focused on exploring the applications of AI-based technology in drug discovery and development, specifically how AI, ML, NLP, data science, and generative deep learning models can optimize the pharmaceutical and biotechnology industries.

AI in Pharma: Discovery

We’re a team of scientists, engineers, machine learning experts and more, working together to advance the state of the art in artificial intelligence. We use our technologies for widespread public benefit and scientific discovery, and collaborate with others on critical challenges, ensuring safety and ethics are the highest priority.

Our long term aim is to solve intelligence, developing more general and capable problem-solving systems, known as artificial general intelligence (AGI). 

Guided by safety and ethics, this invention could help society find answers to some of the world’s most pressing and fundamental scientific challenges.
 
We have a track record of breakthroughs in fundamental AI research, published in journals like Nature, Science, and more.Our programs have learned to diagnose eye diseases as effectively as the world’s top doctors, to save 30% of the energy used to keep data centres cool, and to predict the complex 3D shapes of proteins - which could one day transform how drugs are invented.

Today in partnership with Isomorphic Labs, we're sharing progress on the next generation of #AlphaFold. 🧬

Our new model greatly expands coverage of structure prediction beyond proteins to other key biomolecular classes.

How could it help scientists? → https://lnkd.in/eRmWSYrk

Our AI system #AlphaFold is helping accelerate scientific discovery. How did we ensure it could be used responsibly? 🔬

Pushmeet Kohli explains how we worked with safety experts, biosecurity teams and others to share this breakthrough with the world. ↓

“The UK has started a global conversation on AI safety. The voices engaging from around the world is a step change in the urgency and focus that we’re seeing.”

To mark the end of the #AISafetySummit, our Director of Public Policy Nicklas Berild Lundblad shares his thoughts and those of other leaders at Google about how this technology can be deployed to benefit people everywhere. ↓ 

"This is a pivotal moment in the history of AI. It is no longer a technology of the future." 🌐

To mark this week’s #AISafetySummit, Demis Hassabis and Google's James Manyika met with Michelle Donelan MP and other policymakers, experts and civil society leaders to discuss the opportunities and risks of AI.

We believe action is needed on multiple fronts to solve today’s challenges, tackle the longer-term implications of frontier models, and ensure we build AI responsibly to benefit humanity. ↓ https://dpmd.ai/3MnD9MX

Our CEO Demis Hassabis and Google's James Manyika spoke to CNBC about the need for international collaboration at the #AISafetySummit. 

“It's really important that we have as much dialogue as possible to discuss safety measures, benchmarking, and evaluations of these systems,” Demis tells Arjun Kharpal.

Listen now. ↓ https://dpmd.ai/49lxa4S

Metric
Company Name	Google DeepMind	AI in Pharma: Discovery
Symbol
MSH ID	GOOGLE:DEEPMIND	COM:AIINPHARMA-DISCOVERY
Market	PRIVATE	PRIVATE
Sector	Technology	Healthcare & Health Services
Industry	Artificial intelligence	Pharmaceuticals
Country	GB	US
Stage
Employee Count	2.23K
Website	deepmind.google/technologies	aiinpharma-discovery.com
LinkedIn	googledeepmind
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	45.86
28-Day Growth Score	51.46
90-Day Growth Score	48.71
365-Day Growth Score	48.13

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

GOOGLE:DEEPMIND

Google DeepMind

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue